HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma - Revision history

Bailey.Glen at 17:14, 3 July 2025

2025-07-03T17:14:12Z

← Older revision		Revision as of 12:14, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:33, 25 May 2025

2025-05-25T21:33:37Z

← Older revision		Revision as of 16:33, 25 May 2025
Line 139:		Line 139:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 204:		Line 204:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 245:		Line 245:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 291:		Line 291:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:10, 25 May 2025

2025-05-25T20:10:00Z

← Older revision		Revision as of 15:10, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:35, 24 March 2025

2025-03-24T17:35:46Z

← Older revision		Revision as of 12:35, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Early T-precursor lymphoblastic leukaemia / lymphoma}}		{{DISPLAYTITLE:Early T-precursor lymphoblastic leukaemia / lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Fei Yang, MD, FACMG, Kaiser Permanente Northwest		Fei Yang, MD, FACMG, Kaiser Permanente Northwest

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: /* Gene Mutations (SNV/INDEL) */

2025-02-14T00:16:05Z

Gene Mutations (SNV/INDEL)

@@ Line 246: / Line 246: @@
 </blockquote>
 ==Gene Mutations (SNV/INDEL)==
 Genes encoding transcription factors for development and differentiation (''ETV6, GATA3, HOXA, LMO2, RUNX1, WT1''), kinase signaling (''FLT3, JAK1, JAK3, IL7R, KRAS, NRAS''), and epigenetic modifiers (''DNMT3A, EED, EZH2, PHF6, SUZ12'') are commonly mutated in ETP-ALL <ref name=":5">{{Cite journal|last=Sin|first=Chun-Fung|last2=Man|first2=Pui-Hei Marcus|date=2021|title=Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies|url=https://pubmed.ncbi.nlm.nih.gov/34912707|journal=Frontiers in Oncology|volume=11|pages=750789|doi=10.3389/fonc.2021.750789|issn=2234-943X|pmc=8666570|pmid=34912707}}</ref>. More typical T-ALL mutations, such as ''NOTCH1'' mutations and CDKN1/2 mutations are less frequent in ETP-ALL <ref name=":2">{{Cite journal|last=Jain|first=Nitin|last2=Lamb|first2=Audrey V.|last3=O'Brien|first3=Susan|last4=Ravandi|first4=Farhad|last5=Konopleva|first5=Marina|last6=Jabbour|first6=Elias|last7=Zuo|first7=Zhuang|last8=Jorgensen|first8=Jeffrey|last9=Lin|first9=Pei|date=2016-04-14|title=Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype|url=https://pubmed.ncbi.nlm.nih.gov/26747249|journal=Blood|volume=127|issue=15|pages=1863–1869|doi=10.1182/blood-2015-08-661702|issn=1528-0020|pmc=4915808|pmid=26747249}}</ref>.

Bailey.Glen: Removed old template contents

2025-02-11T21:47:23Z

Removed old template contents

Show changes

Bailey.Glen at 18:45, 10 February 2025

2025-02-10T18:45:08Z

Show changes

Bailey.Glen at 18:17, 10 February 2025

2025-02-10T18:17:06Z

← Older revision		Revision as of 13:17, 10 February 2025
Line 75:		Line 75:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the previous version of the page. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the previous version of the page. Please incorporate above.}}</blockquote>

	The clinical features of ETP-ALL are similar to that of other subtypes of T-ALL, including a high leukocyte count, anterior mediastinal mass or other tissue mass, lymphadenopathy, hepatosplenomegaly<ref name=":3">{{Cite journal\|last=Inukai\|first=Takeshi\|last2=Kiyokawa\|first2=Nobutaka\|last3=Campana\|first3=Dario\|last4=Coustan-Smith\|first4=Elaine\|last5=Kikuchi\|first5=Akira\|last6=Kobayashi\|first6=Miyuki\|last7=Takahashi\|first7=Hiroyuki\|last8=Koh\|first8=Katsuyoshi\|last9=Manabe\|first9=Atsushi\|date=2012-02\|title=Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15\|url=https://pubmed.ncbi.nlm.nih.gov/22128890\|journal=British Journal of Haematology\|volume=156\|issue=3\|pages=358–365\|doi=10.1111/j.1365-2141.2011.08955.x\|issn=1365-2141\|pmid=22128890}}</ref><ref name=":4">Borowitz MJ, et al., (2016).T-lymphoblastic leukemia/lymphoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p176-178.</ref>. Some patients who develop an anterior mediastinal mass can lead to superior vena cava syndrome.		The clinical features of ETP-ALL are similar to that of other subtypes of T-ALL, including a high leukocyte count, anterior mediastinal mass or other tissue mass, lymphadenopathy, hepatosplenomegaly<ref name=":3">{{Cite journal\|last=Inukai\|first=Takeshi\|last2=Kiyokawa\|first2=Nobutaka\|last3=Campana\|first3=Dario\|last4=Coustan-Smith\|first4=Elaine\|last5=Kikuchi\|first5=Akira\|last6=Kobayashi\|first6=Miyuki\|last7=Takahashi\|first7=Hiroyuki\|last8=Koh\|first8=Katsuyoshi\|last9=Manabe\|first9=Atsushi\|date=2012-02\|title=Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15\|url=https://pubmed.ncbi.nlm.nih.gov/22128890\|journal=British Journal of Haematology\|volume=156\|issue=3\|pages=358–365\|doi=10.1111/j.1365-2141.2011.08955.x\|issn=1365-2141\|pmid=22128890}}</ref><ref name=":4">Borowitz MJ, et al., (2016).T-lymphoblastic leukemia/lymphoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p176-178.</ref>. Some patients who develop an anterior mediastinal mass can lead to superior vena cava syndrome.
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 125:		Line 128:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the previous version of the page. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the previous version of the page. Please incorporate above.}}</blockquote>

	''MEF2C'' (5q14) rearrangement or rearrangement involving ''MEF2C''-related cofactors have been reported in about 50% of ETP-ALL cases<ref>Homminga I, Pieters R, Langerak A, de Rooi J, Stubbs A, Verstegen M, et al. MEF2C as Novel Oncogene for Early T-Cell Precursor (ETP) Leukemia. ''Blood'' (2010) 116:9–9. doi: 10.1182/blood.V116.21.9.9</ref>, which have been validated in an independent ETP-ALL patient cohort<ref>Meijer M, Cordo V, Hagelaar R, Smits W, Meijerink J. Manipulating MEF2C: Discovering Novel Drugs to Target ETP-ALL. ''Blood'' (2021) 138 (Supplement 1): 3325. doi.org/10.1182/blood-2021-150176.</ref>. Ectopic MEF2C expression due to rearrangement has been demonstrated as an oncogenic driver of ETP-ALL by upregulating ''LMO2'' and ''LYL1,'' which lead to differentiation block of early thymocytes.		''MEF2C'' (5q14) rearrangement or rearrangement involving ''MEF2C''-related cofactors have been reported in about 50% of ETP-ALL cases<ref>Homminga I, Pieters R, Langerak A, de Rooi J, Stubbs A, Verstegen M, et al. MEF2C as Novel Oncogene for Early T-Cell Precursor (ETP) Leukemia. ''Blood'' (2010) 116:9–9. doi: 10.1182/blood.V116.21.9.9</ref>, which have been validated in an independent ETP-ALL patient cohort<ref>Meijer M, Cordo V, Hagelaar R, Smits W, Meijerink J. Manipulating MEF2C: Discovering Novel Drugs to Target ETP-ALL. ''Blood'' (2021) 138 (Supplement 1): 3325. doi.org/10.1182/blood-2021-150176.</ref>. Ectopic MEF2C expression due to rearrangement has been demonstrated as an oncogenic driver of ETP-ALL by upregulating ''LMO2'' and ''LYL1,'' which lead to differentiation block of early thymocytes.
Line 132:		Line 135:

	Other chromosomal rearrangements involving KMT2A have been observed in ETP-ALL <ref name=":6" />.		Other chromosomal rearrangements involving KMT2A have been observed in ETP-ALL <ref name=":6" />.
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 180:		Line 186:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Individual Region Genomic Gain / Loss / LOH\|The content below was from the previous version of the page. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Individual Region Genomic Gain / Loss / LOH\|The content below was from the previous version of the page. Please incorporate above.}}</blockquote>

	Currently there is no specific copy number alterations/LOH that is associated with ETP-ALL.		Currently there is no specific copy number alterations/LOH that is associated with ETP-ALL.
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 207:		Line 216:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Patterns\|The content below was from the previous version of the page. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Patterns\|The content below was from the previous version of the page. Please incorporate above.}}</blockquote>

	Currently there is no specific chromosomal alteration that is characteristic for ETP-ALL.		Currently there is no specific chromosomal alteration that is characteristic for ETP-ALL.
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==

Bailey.Glen at 22:35, 6 September 2024

2024-09-06T22:35:37Z

← Older revision		Revision as of 17:35, 6 September 2024
Line 15:		Line 15:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	~~[https://ccga~~.~~io/index.php/HAEM4:~~T-~~Lymphoblastic_Leukemia/Lymphoma~~ T-~~Lymphoblastic Leukemia (T~~-~~ALL)]~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub~~-~~Classification~~ / Subtype==		!Disease
			\|-
	Early T-~~Cell Precursor Lymphoblastic Leukemia (ETP-ALL)~~		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|T-cell and NK-cell lymphoid proliferations and lymphomas
			\|-
			\|Family
			\|Precursor T-cell neoplasms
			\|-
			\|Type
			\|T-lymphoblastic leukaemia / lymphoma
			\|-
			\|Subtype(s)
			\|Early T-precursor lymphoblastic leukaemia / lymphoma
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 21:55, 6 September 2024

2024-09-06T21:55:41Z

← Older revision		Revision as of 16:55, 6 September 2024
Line 1:		Line 1:
	{{DISPLAYTITLE:Early T-precursor lymphoblastic leukaemia / lymphoma}}		{{DISPLAYTITLE:Early T-precursor lymphoblastic leukaemia / lymphoma}}
	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

	{{Under Construction}}		{{Under Construction}}

	<blockquote class='blockedit'>{{Box-round\|title=~~HAEM5 Conversion Notes~~\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Early T-Cell Precursor Lymphoblastic Leukemia]].		<blockquote class='blockedit'>{{Box-round\|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Early T-Cell Precursor Lymphoblastic Leukemia]].
	}}</blockquote>		}}</blockquote>

	<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>		<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>

	==Primary Author(s)*==		==Primary Author(s)*==
Line 43:		Line 43:
	==Clinical Features==		==Clinical Features==

	Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>		Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span>
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Signs and Symptoms'''		\|'''Signs and Symptoms'''
	\|EXAMPLE Asymptomatic (incidental finding on complete blood counts)		\|<span class="blue-text">EXAMPLE:</span> Asymptomatic (incidental finding on complete blood counts)

	EXAMPLE B-symptoms (weight loss, fever, night sweats)		<span class="blue-text">EXAMPLE:</span> B-symptoms (weight loss, fever, night sweats)

	EXAMPLE Fatigue		<span class="blue-text">EXAMPLE:</span> Fatigue

	EXAMPLE Lymphadenopathy (uncommon)		<span class="blue-text">EXAMPLE:</span> Lymphadenopathy (uncommon)
	\|-		\|-
	\|'''Laboratory Findings'''		\|'''Laboratory Findings'''
	\|EXAMPLE Cytopenias		\|<span class="blue-text">EXAMPLE:</span> Cytopenias

	EXAMPLE Lymphocytosis (low level)		<span class="blue-text">EXAMPLE:</span> Lymphocytosis (low level)
	\|}		\|}

Line 100:		Line 100:
	!Notes		!Notes
	\|-		\|-
	\|EXAMPLE t(9;22)(q34;q11.2)\|\|EXAMPLE 3'ABL1 / 5'BCR\|\|EXAMPLE der(22)\|\|EXAMPLE 20% (COSMIC)		\|<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)\|\|<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR\|\|<span class="blue-text">EXAMPLE:</span> der(22)\|\|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
	EXAMPLE 30% (add reference)		<span class="blue-text">EXAMPLE:</span> 30% (add reference)
	\|Yes		\|Yes
	\|No		\|No
	\|Yes		\|Yes
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).		The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
Line 121:		Line 121:
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==

	Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'') </span>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 131:		Line 131:
	!Notes		!Notes
	\|-		\|-
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	7		7
	\|EXAMPLE Loss		\|<span class="blue-text">EXAMPLE:</span> Loss
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	chr7:1- 159,335,973 [hg38]		chr7:1- 159,335,973 [hg38]
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	chr7		chr7
Line 144:		Line 144:
	\|Yes		\|Yes
	\|No		\|No
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).		Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
	\|-		\|-
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	8		8
	\|EXAMPLE Gain		\|<span class="blue-text">EXAMPLE:</span> Gain
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	chr8:1-145,138,636 [hg38]		chr8:1-145,138,636 [hg38]
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	chr8		chr8
Line 161:		Line 161:
	\|No		\|No
	\|No		\|No
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	Common recurrent secondary finding for t(8;21) (add reference).		Common recurrent secondary finding for t(8;21) (add reference).
Line 172:		Line 172:
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==

	Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>		Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.'')</span>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 182:		Line 182:
	!Notes		!Notes
	\|-		\|-
	\|EXAMPLE		\|<span class="blue-text">EXAMPLE:</span>

	Co-deletion of 1p and 18q		Co-deletion of 1p and 18q
Line 188:		Line 188:
	\|No		\|No
	\|No		\|No
	\|EXAMPLE:		\|<span class="blue-text">EXAMPLE:</span>

	See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).		See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).